News
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Bristol Myers Squibb BMY obtained the European Commission’s (“EC”) approval for a label expansion of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T
XOM Halts Plans for Massive Blue Hydrogen Plant Amid Weak Demand
Exxon Mobil Corporation (XOM), a U.S. oil and gas giant, stated that it has put a hold on its plans for the construction of the blue hydrogen facility in Baytown, TX, intended to be the largest of
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and older, teens, and adults with spinal muscular atrophy (SMA).
The therapy
GOOGL vs. NVDA: Is There a New Leader in AI?
Just a few months ago, analysts and investors were openly questioning Alphabet’s (GOOGL) future, arguing that large language models would cannibalize search and erode its core business. Today, the
Missed the AI Boom? These 2 Crushed Stocks Could Be Your Second Chance
Last month, when concerns about an AI bubble spilled over and sparked a sell-off, stocks spent several weeks in a pullback. However, the fallout adversely affected some equities more than
ANF Stock Up on Q3 Earnings Beat, Higher Sales on Growth Across Regions
Abercrombie & Fitch Co. ANF posted strong third-quarter fiscal 2025 results, wherein the top and bottom lines beat the Zacks Consensus Estimate. Additionally, on a year-over-year basis, the
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
Shares of Sarepta Therapeutics SRPT rose 7% on Monday after the company announced its progress on a phase I/II study evaluating SRP-1003, an investigational small interfering RNA (siRNA) therapeutic
Is MA Using Beauty Commerce to Unlock Its Next SME Growth Wave?
Mastercard Incorporated MA is diving deeper into sector-specific commerce innovation, and its latest collaboration with L’Oréal could signal a significant change in how beauty products are financed
Apple Bull Case: Vertical Integration, AI Efficiency, & a Huge Cash Stack
Zacks Rank #3 (Hold) stock Apple (AAPL) has undergone dramatic changes throughout its long and storied history. Initially, the company focused on computers, but today, its business primarily
Here's Why Investors Should Give Canadian National Stock a Miss Now
Canadian National Railway CNI is grappling with challenges significantly impacting its financial stability. The increased operating expenses and weak liquidity are major headwinds hurting the
Is UNH's Hybrid Care Strategy Reshaping the Health System Playbook?
UnitedHealth Group Incorporated UNH is continuously strengthening its hybrid care model in the United States, blending technology, data and in-person care to enhance the patient experience. As this
Marvell (MRVL) is an Incredible Growth Stock: 3 Reasons Why
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great
Here is Why Growth Investors Should Buy Equinox Gold (EQX) Now
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to
Here is Why Growth Investors Should Buy New Gold (NGD) Now
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to
3 Reasons Why Growth Investors Shouldn't Overlook Genpact (G)
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to
DASH Total Order Growth Picks Up: Is the Growth Thesis Strengthening?
DoorDash DASH is benefiting from a large customer base and strong growth in average consumer engagement, which has enhanced its order volume. In the third quarter of 2025, total orders increased 21%
Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall
Agilent Technologies A reported fourth-quarter fiscal 2025 earnings of $1.59 per share, which were in line with the Zacks Consensus Estimate. The figure increased 8.9% year over year.Revenues of
AVO's Supply Discipline: A Competitive Edge in an Oversupplied Market?
Mission Produce, Inc. AVO is proving that disciplined execution can be a strategic advantage in a market facing abundant supply and pricing pressure. As global avocado production rises due to strong
Here's Why Investors Should Give Landstar Stock a Miss Now
Landstar System, Inc. (LSTR) is currently mired in multiple headwinds, which, we believe, have made it an unimpressive investment option.
Let’s delve deeper.
LSTR: Key Risks to Watch
Southward
Intuit Expands SMB MediaLabs Reach via The Trade Desk Partnership
Intuit Inc. INTU recently announced a strategic partnership with The Trade Desk, making Intuit’s SMB MediaLabs audiences available on The Trade Desk platform. With this partnership, Intuit is
Geospace Stock Declines Post Q4 Earnings Despite Narrower Loss
Shares of Geospace Technologies Corporation GEOS have lost 38.7% since the company reported its earnings for the quarter ended Sept. 30, 2025. This compares to the S&P 500 Index’s 1.4% gain over the
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates in healthcare-adjacent markets by delivering access to clinical care and wellness services through a digital
BNPL is Not Enough, So Klarna Launches a Coin: KlarnaUSD Stablecoin
Klarna Group plc KLAR has introduced KlarnaUSD, its very first stablecoin, a digital token pegged to the U.S. dollar. This marks its serious entry into the crypto payments space. Built on Tempo, a
Will Renewed NQI Funding Fuel Rigetti's Government Sales Pipeline?
Rigetti Computing RGTI is leaning heavily on government partnerships as a core piece of its commercialization path, and the timing could work in its favor. Per the third-quarter earnings call


